Teva upgraded to Neutral from Underweight at JPMorgan JPMorgan upgraded Teva to Neutral citing favorable initial Copaxone 3x weekly trends and the potential for further cost cuts. The firm raised its price target for shares to $49 from $38.
Teva board authorizes increase in share repurchase program to $3B The Company announced today that, as authorized by the Board of Directors, it will increase its share repurchase program by $1.7 billion to $3 billion. The program has no time limitations. The Company intends to begin purchasing shares promptly.